Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun:63:123-139.
doi: 10.1016/j.breast.2022.03.008. Epub 2022 Mar 18.

Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

Walter Paul Weber  1 Jane Shaw  2 Andrea Pusic  3 Lynda Wyld  4 Monica Morrow  5 Tari King  6 Zoltán Mátrai  7 Jörg Heil  8 Florian Fitzal  9 Shelley Potter  10 Isabel T Rubio  11 Maria-Joao Cardoso  12 Oreste Davide Gentilini  13 Viviana Galimberti  14 Virgilio Sacchini  5 Emiel J T Rutgers  15 John Benson  16 Tanir M Allweis  17 Martin Haug  18 Regis R Paulinelli  19 Tibor Kovacs  20 Yves Harder  21 Bahadir M Gulluoglu  22 Eduardo Gonzalez  23 Andree Faridi  24 Elisabeth Elder  25 Peter Dubsky  26 Jens-Uwe Blohmer  27 Vesna Bjelic-Radisic  28 Mitchel Barry  29 Susanne Dieroff Hay  30 Kimberly Bowles  31 James French  25 Roland Reitsamer  32 Rupert Koller  33 Peter Schrenk  34 Daniela Kauer-Dorner  35 Jorge Biazus  36 Fabricio Brenelli  37 Jaime Letzkus  38 Ramon Saccilotto  39 Sarianna Joukainen  40 Susanna Kauhanen  41 Ulla Karhunen-Enckell  42 Juergen Hoffmann  43 Ulrich Kneser  44 Thorsten Kühn  45 Michalis Kontos  46 Ekaterini Christina Tampaki  47 Moshe Carmon  48 Tal Hadar  17 Giuseppe Catanuto  49 Carlos A Garcia-Etienne  50 Linetta Koppert  51 Pedro F Gouveia  12 Jakob Lagergren  52 Tor Svensjö  53 Nadia Maggi  54 Elisabeth A Kappos  18 Fabienne D Schwab  54 Liliana Castrezana  54 Daniel Steffens  54 Janna Krol  54 Christoph Tausch  55 Andreas Günthert  56 Michael Knauer  57 Maria C Katapodi  58 Susanne Bucher  59 Nik Hauser  60 Christian Kurzeder  61 Rosine Mucklow  2 Pelagia G Tsoutsou  62 Atakan Sezer  63 Güldeniz Karadeniz Çakmak  64 Hasan Karanlik  65 Patricia Fairbrother  66 Laszlo Romics  67 Giacomo Montagna  5 Cicero Urban  68 Melanie Walker  69 Silvia C Formenti  70 Guenther Gruber  71 Frank Zimmermann  72 Daniel Rudolf Zwahlen  73 Sherko Kuemmel  74 Mahmoud El-Tamer  5 Marie Jeanne Vrancken Peeters  75 Orit Kaidar-Person  76 Michael Gnant  77 Philip Poortmans  78 Jana de Boniface  79
Affiliations

Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

Walter Paul Weber et al. Breast. 2022 Jun.

Abstract

Aim: Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario.

Methods: A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology.

Results: The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR.

Conclusions: The panel endorsed the need for prospective, ideally randomised phase III studies and for surgical and radiation oncology teams to work together for determination of optimal sequencing and techniques for PMRT for each patient in the context of BR.

Keywords: Autologous breast reconstruction; Breast cancer; Implant-based breast reconstruction; Nipple-sparing mastectomy; Post-mastectomy radiotherapy.

PubMed Disclaimer

Conflict of interest statement

No competing interests in the current work were reported. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

F. Brenelli had personal honoraria for Roche, MSD and Zodiac.

P. Dubsky received other from Amgen, AstraZeneca, Pfizer, Roche and Merck, grants from Cepheid/Danaher, Agendia, Myriad and from Oncomark.

M. Gnant reports personal fees/travel support from Amgen, DaiichiSankyo, AstraZeneca, EliLilly, LifeBrain, Nanostring, Novartis; an immediate family member is employed by Sandoz.

Support for meetings and teaching tasks has been paid to the research Department directed by Y. Harder from Establishment Labs, S.A, Costa Rica, Integra Life Sciences, USA and Hilotherm GmbH, Germany.

S Kuemmel has minority non-profit ownership at WSG Study Group; has a consulting/advisory board role at Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Genomic Health, Lilly, MSD, Novartis, Seagen. Pfizer, pfm Medical, Roche, Somatex, Seagen, Hologic; and received fees from Roche, Somatex, Novartis, Lilly, and personal fees from Roche, Novartis and Hologic.

Ch. Kurzeder receives honoraria from Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A, Pfizer, Daichi, and travel fees from GSK, Astra Zeneca, Roche. He has a consulting or advisory role for Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A, Merck MSD, Pfizer.

Travel, Accommodations, Expenses: GSK, Astra Zeneca, Roche.

A. Pusic is a co-developer of the BREAST-Q and receives royalties when it is used in for-profit, industry-sponsored clinical trials.

M. Walker has received personal honoraria from Guerbet and Roche Products Pty Ltd.

W. P. Weber received research from Takeda Pharmaceuticals International paid to the Swiss Group for Clinical Cancer Research (SAKK) and personal honoraria from Genomic Health, Inc, USA. for meetings was paid to his institution from Sandoz, Genomic Health, Medtronic Medtronic, Novartis Oncology, Pfizer and Eli Lilly.

S. Formenti reports: Consultant for: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, Merck US, EMD Serono/Merck, Genentech/ROCHE, Boheringer, Accuray.

Grant/Research support from: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ArcusM.Morrow reports personal fees from Exact Sciences and Roche.

All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Questions developed or adjusted ad hoc during consensus conference Abbreviations used in questionnaire: NSM (nipple-sparing mastectomy), PMRT (post-mastectomy radiotheraphy), BR (Breast reconstruction), IBRR (implant-based breast reconstruction)
Fig. 1
Fig. 1
Questions developed or adjusted ad hoc during consensus conference Abbreviations used in questionnaire: NSM (nipple-sparing mastectomy), PMRT (post-mastectomy radiotheraphy), BR (Breast reconstruction), IBRR (implant-based breast reconstruction)
Fig. 2
Fig. 2
Questions on nipple- and skin-sparing mastectomy.
Fig. 3
Fig. 3
Type of breast reconstruction.
Fig. 3
Fig. 3
Type of breast reconstruction.
Fig. 4
Fig. 4
Timing of breast reconstruction.
Fig. 4
Fig. 4
Timing of breast reconstruction.
Fig. 5
Fig. 5
Special considerations.
Fig. 6
Fig. 6
Post-mastectomy radiation therapy.
Fig. 6
Fig. 6
Post-mastectomy radiation therapy.
Fig. 7
Fig. 7
Post-mastectomy radiotherapy planning in patient with bilateral implant-based breast reconstruction.

References

    1. Kummerow K.L., Du L., Penson D.F., et al. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9–16. - PubMed
    1. Sisco M., Kyrillos A.M., Lapin B.R., et al. Trends and variation in the use of nipple-sparing mastectomy for breast cancer in the United States. Breast Cancer Res Treat. 2016;160:111–120. - PubMed
    1. McGale P., Taylor C., Correa C., et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–2135. - PMC - PubMed
    1. Budach W., Kammers K., Boelke E., Matuschek C. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials. Radiat Oncol. 2013;8:267. - PMC - PubMed
    1. Poortmans P.M., Collette S., Kirkove C., et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–327. - PubMed

LinkOut - more resources